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Introduction: 
Coronary artery bypass graft surgery (CABG) is in use for more than five decades 
for treatment of patients with coronary artery disease (CAD). Unsolved problem is 
progression of the disease in bypass grafts and in native coronary arteries. 
Atherosclerosis is a process which develops in bypass grafts (arterials and veins) 
as much as in native coronary arteries. Saphenous vein graft disease is composed 
of three patophysiologically linked processes: thrombosis, intimal hyperplasia, 
and atherosclerosis.  Atherosclerosis and thrombosis are basic processes in 
coronary artery disease and arterial grafts disease.  
Which are the factors that mediate coronary artery graft disease and progression of 
the disease in native coronary circulation? What is the prognostic meaning of the 
disease progression and what are the measures that can and have to be done to 
slow down these processes? 
 
Methods: 
We analyzed 102 patients with CAD treated with CABG, who underwent re-
coronarography (re-CA) because of AMI, non-stable angina pectoris and/or heart 
failure. Mean period from CABG to re-CA was 5,97±4,27 years (minimum one, 
maximum seventeen years). Mean age of the patients was 55,98±8,95 years. 
Following data were analyzed:  
-pre operative characteristics: risk factors (age, gender, hypertension, 
hyperlipidemia, diabetes mellitus, obesity, cigarette smoking), clinical and 
functional status (angina pectoris-CCSC classification and heart failure (HF)-
NYHA classification, n-r of ischemic episodes registered by 24-hour ambulatory 
ECG-Holter monitoring or during exercise stress testing, VT–registered on ECG-
Holter monitoring or during exercise stress testing, METs and MOI calculated 
from exercise stress testing), left ventricular (LV) morphologic and functional 
parameters (EF, LV dimensions, segmental kinetics, LV aneurism), and 
angiographic status (number of diseased vessels, degree of stenosis, calculated 
Gensini score, EF, LV aneurism);  
-per operative characteristics: number and type of conduits, type of 
revascularization-complete arterial, vein or combined, completeness of 
revascularization;  
-post operative characteristics: risk factors (age, gender, hypertension, 
hyperlipidemia, diabetes mellitus, obesity, cigarette smoking), clinical and 
functional status (angina pectoris-CCSC classification and heart failure (HF)-
NYHA classification, n-r of ischemic episodes registered by 24-hour ambulatory 
ECG-Holter monitoring or during exercise stress testing, VT –registered on ECG-
Holter monitoring or during exercise stress testing, METs and MOI calculated 
from exercise stress testing), LV morphologic and functional parameters (EF, LV 
dimensions, segmental kinetics, LV aneurism) and angiographic status (number of 
diseased vessels, degree of stenosis in grafts and native coronary arteries (NCA), 
calculated Gensini score). 
Data were gathered threw patients history of disease, physical examination, and 
consultation of medical reports from clinical investigations: laboratory results, 
ECG, 24-hour ECG-Hollter monitoring, exercise stress testing, 2-D and Doppler 
Echocardiography and coronary arteriograpy (CA). 
Statistical analysis. Data were analyzed using SPSS software. Continuous 
variables were reported as mean±SD. Categorical variables were reported as 
counts (percentages) and compared between groups using a chi-square test. 
Continuous variables were examined by a two-tailed t test or by the Mann-
Whitney test if not normally distributed. The Spearman rank correlation 
coefficient was used to estimate the correlation between variables. Freedom from 
unfavorable coronary events was analyzed by means of Kaplan-Meier curves, 
with differences between groups tested by long-rank test. The Cox proportional 
hazard regression models, using a multivariate forward stepping model, were used 
to examine the time-dependent association between the multiple clinical, 
functional, echocardiographic, angiographic and per-operative variables and 
adverse cardiac event occurrence, including cardiac death. For all analyses a p 
value <0,05 was considered statistically significant.   
 
Results: 
Demographic data 
Re-coronary arteriography was most frequently performed during the first 
postoperative year (24,5% of pts), then in seventh (10,8% of pts) and in tenth 
(10,8% of pts), which is in correlation with the natural history of the disease. Most 
of re-CA were performed during the first 7 years (68pts-66,6%). 
Coronary arteriography findings are presented at Table 1. In average 1,12±0,98 
grafts were occluded, and 0,37±0,58 were patent-diseased. In 71 patient native 
coronary artery progressions disease was found. 41 patients had one occluded 
graft, 22-two, 7-three and 2 had four occluded grafts. Percentual distribution of 
patients according to the number of occluded conduits is presented on Figure 1. 
From 102 patients who underwent re-CA after CABG, 72 (70,6%) patients had 
graft closure, 33 (32,3%) had non-occlusive graft disease, and in 71 (69,6%) 
patient progression in native coronary arteries was found. 
Although re-CA was most often performed during the first postoperative year, 
significant difference in disease progression as a function of years after CABG 
wasn’t found (p=ns), which is well documented in Table 2. 
Identified prognosticators 
We analyzed correlations between graft disease/NCA progression disease from 
one side, and: risk factors before and after the operation, used medications, data 
from ambulatory ECG-Hollter monitoring, LV morphologic and functional data, 
exercise ECG and coronary arteriography data before and after the operation and 
per-operative characteristics on the other. Variables for which statistically 
significant correlations were found are presented on Tables 3 and 4. Surprisingly, 
we found no significant correlations between graft disease and pre/post-operative 
persistence of risk factors, and pre/post-operative used medications (antiplatelet 
and lipid lowering therapy). When progression of the disease in native coronary 
arteries was analyzed, absence of antiplatelet therapy in postoperative period was 
identified as a significant negative predictor (p=0,026). Graft disease was 
associated with greater number of diseased vessels before the operation and 
application of vein grafts. On table 5 we can see that application of vein grafts 
alone or in combination with left internal mammary artery are significantly 
associated with graft disease (Pearson Chi-Square p=0.013; Likelihood Ratio 
p=0.008), which means that more extensive disease before the operation, and 
greater number of applied conduits leads to earlier graft disease. Progression of 
the disease in native coronary arteries was associated with more widespread 
disease preoperatively (greater Gensini score) and more applied conduits.  
Multivariate analyze with Cox’s regression analyze model identified as 
independent predictors of graft occlusion (with statistical significance of the 
model p=0,0001): 
-number of diseased vessels before the operation (p=0,010)-more diseased vessels 
leads to higher probability of early graft occlusion (Graphic 1); 
-number of applied conduits (p=0,011)-more applied conduits leads to their earlier 
closure (Graphic 2); 
-antiplatelet therapy (p=0,019)-absence of these agent leads to earlier graft closure 
(Graphic 3). 
Multivariate analyze with Cox’s regression analyze model identified as 
independent predictors of native coronary artery progression disease (with 
statistical significance of the model p=0,0001): 
-Gensini score (p=0,0001)-diffuse distribution of the disease before the operation, 
leads to its earlier progression; 
- antiplatelet therapy (p=0,050)-absence of this agent leads to earlier progression 
of the disease in native coronary circulation; 
-type of applied conduit (p=0,011)-vein conduits are associated with earlier 
progression of the disease (Graphic 4); 
-presence of diabetes mellitus (p=0,020) leads to earlier progression of the disease 
(Graphic 5). 
Prognostic implications: 
What are the prognostic implications of graft/NCA progression disease? Is there 
association between disease progression and cardiac events? 
No significant correlation was found between graft occlusion and cardiac events 
in general. Of 102 patients, 71 have had graft occlusion, 68 of which experienced 
some cardiac event, but from 31 patients without graft occlusion, 29 have had 
cardiac event. Inter-group differences were non-significant (Pearson Chi Square 
p= 0.898; Pearson's R= 0.899; Odds Ratio=1.052 (0.462-2.365, CI 95%). 
Statistical significance was found (Pearson Chi Square p=0.253; Spearman 
Correlation= 0.050) when analyze was performed for different types of cardiac 
events. Namely, hard events: cardiac death, myocardial infarction and heart failure 
were significantly more frequent in comparison with soft events or no events 
(Table 5). 
No significant correlation was found between non-occlusive graft disease and 
cardiac events in general, also. 32 of 34 patients with potent-diseased grafts have 
had cardiac events, but also 65 of 68 patients without graft disease have 
experienced cardiac event (Pearson Chi Square p= 0.990; Pearson's R = 0.990; 
Odds Ratio= 0.990 (0.195-5.027, CI 95%). Significant correlations weren’t found 
neither for the type of cardiac event (Pearson Chi Square p=0.661; Spearman 
Correlation 0.573), although non-stable angina pectoris was somewhat more 
frequent in these patients (Table 6). 
Statistically significant correlation also wasn’t found for progression of the 
disease in native coronary arteries and cardiac events. 69 of 72 patients with 
native coronary artery disease progression had some type of cardiac event, but 
also 28 of 30 patients without such progression had experienced cardiac event 
(Pearson Chi Square p= 0.867; Pearson's R = 0.868; Odds Ratio= 1.067 (0.475-
2.399, CI 95%). As for the type of the event, acute myocardial infarction and non-
stable angina pectoris were more frequent in these patients but without statistical 
significance (Pearson Chi Square p=0.563; Spearman Correlation= 0.166) (Table 
7). 
Percutany coronary interventions were performed in 45 (44,1%) patients, 21 
patient went threw PTCA, and in 24 patients endovascular proteses were 
implanted. In average 1,3 PTCA were performed per patient (from one to three), 
and 1,6 stents were implanted (from one to five). PCI procedures were 
significantly more frequently performed on native coronary arteries-in 30/71 
patients, than on grafts-in15/105 patients (p<0,000001) (Table 8). 
 
Discussion: 
Which are the factors that influence graft potency? Are there differences between 
factors that determine saphenous vein grafts potency versus arterial grafts?  
Saphenous vein graft potency-disease 
Endothelial proliferation is a process which starts as soon as the vein graft is 
connected to the arterial circulation. Peri-procedural trauma may exaggerate this 
process and start early graft atherosclerosis. Arterial smooth muscles are adapted 
to pulsatile flow, but smooth muscle in transplanted veins reacts with proliferative 
response. Veins are also poorly suited to inhibition of platelet-mediated 
thrombotic events. These elements constitute three patophysiologically linked 
processes: thrombosis, intimate hyperplasia and atherosclerosis. These elements 
are responsible for saphenous vein graft disease, especially after the fifth to 
seventh postoperative year (1-3). Study of Fitzgibbon et al. refers early vein graft 
potency of 88%, 81% after one year, 75% at five years, and 50% at 10-15 years. 
He classified aortocoronary vein grafts as: occluded, patent and diseased, patent 
with high profile lesion (>59% graft stenosis), and non-diseased vein grafts (3). 
Factors influencing early potency of saphenous vein grafts are: endothelial injury, 
technical errors and poor arterial runoff. Absence of antiplatelet therapy leads to 
distal anastomosis occlusion. Late graft potency is mainly influenced by conduit 
atherosclerosis, plaque rupture and late thrombosis, and contributors to these 
situations are hyperlipidemia, inadequate lipid-lowering therapy, cigarette 
smoking and diabetes mellitus. Tsukamoto et al. find out that HLP and persistence 
of   three risk factors after CABG, leads to earlier vein graft disease (5). 
Bypassing of right coronary artery, left circumflex artery and non-sequential 
grafting also leads to graft closure (1,2,3). There are plenty of evidences 
witnessing importance of risk factors reduction for the benefit of graft potency. In 
NHLBI (Post Coronary Artery Bypass Graft Clinical Trial), aggressive LDL 
Cholesterol reduction (1,6-2,2 mmol/L), was significantly associated with better 
and longer graft potency (4).  
Arterial graft potency-disease  
The left internal thoracic artery bypassed to the left anterior descending coronary 
artery is the single greatest positive predictor of longevity of graft potency. 
Internal thoracic artery is biologically better graft compared with vein conduits. It 
is metabolically active conduit which releases endothelium derived nitric oxide 
and prostacyclines, which inhibits smooth muscle proliferation, inhibits 
atherosclerosis and thrombosis, which are the two main determinants of arterial 
grafts disease (3). Kwang Ree Cho documented better arterial versus vein grafts 
potency after the first and fifth year. He, and hiss colleges also refer better arterial 
grafts potency when connected to LAD, and similar potency vs. vein grafts when 
connected to other coronary arteries. The lowest graft potency is when RCA is 
bypassed (7). In IMAGE study (8), Berger and al. refers that there isn’t significant 
difference in graft potency during the first postoperative year between arterial and 
vein grafts, but differences appears after seventh year. This same result was 
referred in CABADAS study also (10). Alderman (9) find out that retained graft 
potency is a result of use of internal thoracic artery, larger size of recipient 
coronary artery, and better blood flow through the grafts and aspirin therapy.  
Complete arterial revascularization  using BIMA (left and right internal thoracic 
artery), which can be supplemented by radial or gastroepiploic artery with the 
method of sceletonisation and T grafts, at this moment is considered as the 
ultimate treatment of myocardial revascularization despite all disagreements, 
mostly about technical aspects of the treatment. Survival curves between 
combined and complete arterial revascularization begins to separate over 10-12 
years after CABG (3, 11,12). Importance of risk factors reduction, especially LDL 
cholesterol and diabetes, is also well documented and for arterial grafts potency 
(13).       
Native coronary artery progression disease 
Progression of the disease in native coronary arteries is a combined process of 
atherosclerosis and thrombosis. Pregowski found no difference in the structure of 
ruptured atherosclerotic plaque in natural coronary arteries, arterial or vein grafts 
(14). Factors influencing progression in native coronary arteries are bed control of 
risk factors, hyperlipidemia, diabetes mellitus, inappropriate lipid-lowering 
therapy, incomplete revascularization, subtotal occlusions found preoperatively, 
inappropriate graft insertion (1,3). 
What is the clinical significance of graft disease? 
Graft disease and progression of the disease in native coronary circulation is 
associated with worse clinical outcome. The greatest incidence of adverse 
reactions is registered when grafts to LAD are diseased. Surprising was the fact 
brought by Zafrir and al., who referred existence of myocardial ischemia in LIMA 
to LAD vascular territory  bypass grafting even in the absence of significant 
stenosis of LIMA. They found out that discrepancy and decreased ratio 
LAD/LIMA is a reason for the ischemia, and occurs when LIMA diameter is 
smaller than LAD diameter. Such situations can also be present in “steel 
syndromes” mostly from subclavian artery and powerful intercostals branches, 
arterial tendency for vasospasm, hypotension, myocardial stunning and bypassing 
of non-totally occluded arteries (1,3,15). With almost the same incidence of graft 
disease, women have worse clinical outcome, with greater incidence of cardiac 
death, myocardial infarction and more frequent need for re-revascularization (16, 
17). Angina pectoris is soft event which appears in the first two years after the 
operation in about 3-4% of patients, and its appearance threw the following years 
progressively rises. It is a result of progression of the disease, more often is 
present in patients with uncontrolled risk factors, especially obesity, absence of 
lipid-lowering therapy, incomplete and/or vein grafts revascularization, and also is 
dependent from previous anginal status and left ventricular function. Hard events 
(cardiac death, myocardial infarction and non-stable angina pectoris) are less 
frequent, but mostly associated with vein grafts, and occlusion of the graft for 
LAD (1, 2, 3, 9). 
Measures to stop the progression of the disease: 
Regression of plaque area may be achieved by: depletion of cholesterol esters, 
which may stabilize the plaque and reduce the stenosis by 10-20%, lyses of 
occlusive or mural thrombi wound healing that may favorably remodel an acutely 
disrupted plaque and arterial remodeling through relaxation of arterial vasomotor 
tone (3). Measures to stop progression of the disease are focused on diminishing 
of restenosis and thrombosis with pharmacotherapy (mainly with antiplatelet 
agents, not with anticoagulants, lipid-lowering therapy, vasodilator therapy (in 
arterial conduits with long acting nitrates, not with diltiazem), and with percutany 
coronary interventions (PTCA and/or stenting) (3). For a long period of time 
interventional cardiologists were not very happy to intervene in grafts. But now 
there are several reports on this subject. ATLAS Trial reports that PCI procedures 
performed on SVG are safer with premedication with GP IIb/IIIa inhibitors, but 
not with the acolysis. Leineweber suggests that stenting of the SVG ruptured 
plaque has to be performed with distal protection, because of rich with 
vasoconstricting mediators-debris releasing and worsening of micro vascular 
perfusion (16,18,19).  
Distribution of re-coronary arteriographies during years after CABG in our 
patients was typical for the natural evolution of the disease. The most frequent 
were during the first postoperative year, which correlates with the period of early 
graft disease, in vein, but also in the arterial conduits (especially when radial 
artery was applied). Second critical period was between fifth and seventh year, 
which is the period of occurrence of vein graft disease, and the third critical period 
was tenth year-period when arterial grafts disease is expected. 
There weren’t significant differences in factors influencing graft disease and 
progression of the disease in native coronary arteries. In our patients, usage of 
vein grafts as conduits, more conduits (which means less sequentional grafting), 
bypassing of obstructed but not-occluded coronary arteries (“steal” threw native 
artery), absence of aspirin and lipid-lowering therapy and diabetes were identified 
as factors that accelerate and aggravate grafts and native coronary arteries disease.   
Graft occlusion was associated with cardiac death, acute myocardial infarction 
and heart failure, while non-occlusive graft disease and native coronary artery 
progression disease was associated with angina pectoris. But surprisingly, we 
failed to find statistically significant differences in occurrence of cardiac events in 
our patients as a function of  presence/absence of graft disease. The number of 
registered cardiac events in our  study was very high. Reasonable explanation lies 
in the study design. This was opservational study which analyzed patients who 
underwent re-CA after CABG because of some event: AMI, APNS or heart 
failure, so at the time of performing the re-CA, patients were already experiencing 
some type of cardiac event. If patient selection was done from stable patients 
(relatively asymptomatic), results about the prognostic implication of graft disease 
probably would be much different. We feel that this is a great limitation of our 
study. 
In our patients PCI procedures were conducted significantly more often on native 
coronary arteries in comparison with vein grafts, which can be explained with 
suitability of the diseased vessels for PCI procedure. 
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Structured abstract  
 
Objectives: to identify factors that influence graft disease and native coronary 
arteries progression disease and prognostic implication of this process. 
Background: Unsolved problem in CABG patients is progression of the disease 
in bypass grafts and native coronary arteries.  
Methods: Data from 102 patients with CABG, who underwent re-
coronarography, were analyzed:  
-Pre and post-operative variables: risk factors, clinical status, functional capacity, 
left ventricular parameters and angiographic status (before and after CABG);  
-Per-operative characteristics: number and type of conduits, type of 
revascularization, number of applied conduits;  
Statistical analysis. Two-tailed t test, chi-square test, Spearman rank correlation 
coefficient, Kaplan-Meier curves, Cox proportional hazard regression model, were 
used, p<0,05 was considered statistically significant.   
Results: Coronary arteriography was most often performed during the first, 
seventh and tenth post-operative year. There wasn’t any significant difference in 
disease progression as a function of years after CABG. Diabetes, antiplatelet and 
lipid-lowering therapy, n-r of diseased vessels, disease widespreadnes before the 
operation, vein grafts and number of applied grafts were identified as predictors of 
graft disease/native coronary arteries progression disease. Significant correlation 
with the type of cardiac event was found. Cardiac death, myocardial infarction and 
heart failure were more frequent in patients with graft occlusion, non-stable 
angina pectoris in non-occlusive graft disease, which together with acute 
myocardial infarction was more often in patients with native coronary arteries 
progression disease. PCI was significantly more often performed on native 
coronary arteries. 
Conclusion:  
Graft disease and native coronary artery progression disease is a continuous 
process which can be slowed by aggressive risk factors reduction, medications, 
and PCI procedures. In contrary, it leads to unfavorable clinical outcome. 
 Kay words: graft disease, risk factors, cardiac events 
 
Condensed abstract  
 
Graft disease/native coronary artery progression disease is a continuous process 
that leads to unfavorable clinical outcome. Diabetes, antiplatelet and lipid-
lowering therapy, number of diseased vessels before the operation, vein grafts, 
number of applied grafts were identified as predictors of this process, which can 
be slowed by risk factors reduction, medications, and PCI procedures, that can be 
safely performed on grafts as on native coronary arteries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
